NCT02634294View on ClinicalTrials.gov

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Hematological NeoplasmsRecurrence
Interventions
DRUG

Peg interferon alfa-2b

Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1\~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.

Trial Locations (1)

200080

Shanghai Jiao Tong University Affilated First People's Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT02634294 - Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT | Biotech Hunter | Biotech Hunter